Abstract: Provided are a new class of hydrazone amide derivatives and the use thereof in the preparation of anti-osteoporosis drugs, wherein the structural formula of the hydrazone amide derivative is as shown in formula (I), and same are a new class of compounds with an anti-osteoporosis effect.
Type:
Grant
Filed:
December 27, 2021
Date of Patent:
March 18, 2025
Assignee:
SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
Inventors:
Dane Huang, Chao Zhao, Qiong Gu, Jun Xu
Abstract: Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X)n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.
Type:
Application
Filed:
May 24, 2023
Publication date:
October 12, 2023
Applicant:
SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
Inventors:
Jun XU, Mengjiao HAO, Yuting ZHANG, Hao CHEN